News
NCEL
3.310
+5.08%
0.160
NewcelX Stem Cell Platform Strengthened by Peer-Reviewed AstroRx Study in Multiple Sclerosis
TipRanks · 3d ago
NewcelX reports Stem Cell Reports study shows AstroRx cell therapy boosts remyelination in MS models
PUBT · 3d ago
NewcelX Announces Publication Of Peer-Reviewed Study On The Potential Of AstroRx, A Human Embryonic Stem Cells-Derived Astrocyte Therapy, In The Journal Stem Cell Reports
Benzinga · 3d ago
Weekly Report: what happened at NCEL last week (0608-0612)?
Weekly Report · 3d ago
Top Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads
NASDAQ · 06/09 02:41
Weekly Report: what happened at NCEL last week (0601-0605)?
Weekly Report · 06/08 10:03
NewcelX Calls June 30, 2026 Shareholders’ Meeting as 2025 Losses Deepen
TipRanks · 06/05 21:27
Weekly Report: what happened at NCEL last week (0525-0529)?
Weekly Report · 06/01 10:07
NewcelX submits NCEL-101 pre-investigational new drug briefing package to FDA
TipRanks · 05/27 14:42
NewcelX Files Pre-IND With FDA for NCEL-101 Type 1 Diabetes Cell Therapy
TipRanks · 05/27 12:29
NewcelX submits FDA pre-IND package for NCEL-101 type 1 diabetes trial
PUBT · 05/27 11:55
NEWCELX AG - TYPE B PRE-IND MEETING WITH FDA SCHEDULED FOR LAST WEEK OF JUNE
Reuters · 05/27 11:55
EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND Submission
Benzinga · 05/27 11:31
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
Barchart · 05/27 06:55
Weekly Report: what happened at NCEL last week (0518-0522)?
Weekly Report · 05/25 10:10
Weekly Report: what happened at NCEL last week (0511-0515)?
Weekly Report · 05/18 10:09
NewcelX files to sell 2.26M common shares for holders
TipRanks · 05/11 22:55
Weekly Report: what happened at NCEL last week (0504-0508)?
Weekly Report · 05/11 10:07
Weekly Report: what happened at NCEL last week (0427-0501)?
Weekly Report · 05/04 10:05
NLS Pharmaceutics GAAP EPS of -$2.16
Seeking Alpha · 05/01 12:48
More
Webull provides a variety of real-time NCEL stock news. You can receive the latest news about NewcelX Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NCEL
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.